SCHEMBL8304315

SCHEMBL8304315

CC(C)C[C@H](COc1ccc(CC2SC(=O)NC2=O)cc1)NC[C@H](O)c1cccc(Cl)c1

nearest known ligand 0.59

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
PPARG P37231 4/20 0.59
ADRB2 P07550 9/20 0.49
ADRB3 P13945 9/20 0.49
ADRB1 P08588 6/20 0.49
SLC2A1 P11166 2/20 0.49
FFAR1 O14842 3/20 0.48
CYP2D6 P10635 2/20 0.47
ADRA1D P25100 1/20 0.47
ADRA1A P35348 1/20 0.47
ADRA1B P35368 1/20 0.47
CYP1A2 P05177 1/20 0.47
CYP2C9 P11712 1/20 0.47
CYP2C19 P33261 1/20 0.47
GLA P06280 1/20 0.47
CYP3A4 P08684 1/20 0.46
HIF1A Q16665 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8308525 1.00 PPARG (0.59) PPARGADRB2ADRB3ADRB1SLC2A1
SCHEMBL8304312 1.00 PPARG (0.59) PPARGADRB2ADRB3ADRB1SLC2A1
SCHEMBL8305247 0.90 PPARG (0.63) PPARGADRB2ADRB3ADRB1SLC2A1
SCHEMBL8406934 0.90 PPARG (0.63) PPARGADRB2ADRB3ADRB1SLC2A1
SCHEMBL8305440 0.90 PPARG (0.63) PPARGADRB2ADRB3ADRB1SLC2A1
SCHEMBL8305245 0.90 PPARG (0.63) PPARGADRB2ADRB3ADRB1SLC2A1
SCHEMBL9413146 0.86 PPARG (0.47) PPARGFFAR1CYP2C9
SCHEMBL9413145 0.86 PPARG (0.47) PPARGFFAR1CYP2C9
SCHEMBL6930080 0.85 PPARG (0.76) PPARGFFAR1CYP2C9
SCHEMBL6929663 0.85 PPARG (0.76) PPARGFFAR1CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0590793-B1 Oxazolidine derivatives having anti-diabetic and anti-obesity properties, their preparation and their therapeutic uses SANKYO CO (JP) 1999-10-13 EP disclosed
US-5436257-A Low toxicity SANKYO COMPANY, LIMITED (JP) 1995-07-25 US disclosed
EP-0590793-A1 Oxazolidine derivatives having anti-diabetic and anti-obesity properties, their preparation and their therapeutic uses SANKYO COMPANY LIMITED (JP) 1994-04-06 EP disclosed